secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2022-02-07T23:59:59+00:00
Accession:  0001714899-22-000021
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali Therapeutics appoints Erik Harris to Board of Directors
--------------------------------------------------------------

- Erik Harris appointed to Board and Audit Committee effective Feb 3, 2022, as Class II director.
- Annual cash compensation of $45,000 for Board service, plus $10,000 for Audit Committee.
- Initial equity awards valued at ~$700,000 aggregate (60% option, 40% RSU) with 4-year vesting.
- Harris is Chief Commercial Officer and EVP at Ultragenyx, with 20 years biotech commercial experience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000171489922000021/0001714899-22-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000171489922000021/dnli-20220207.htm
  HTML page:      https://secwatch.observer/filing/0001714899-22-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer